**SECTION C: ANIMAL/MECHANISTIC CA-INHIBITION STUDIES FOR CSF PRODUCTION
& ICP**

STUDY_ID,FIRST_AUTHOR,YEAR,JOURNAL,SPECIES,MODEL_CATEGORY,PREPARATION_TYPE,N_TOTAL_UNITS,PRIMARY_CAI_OR_KEY_DRUGS,PRIMARY_MEASUREMENT_METHOD,PRIMARY_MEASUREMENT_DOMAIN,PRIMARY_ENDPOINT_NAME,PRIMARY_ENDPOINT_TYPE,PRIMARY_ENDPOINT_MAIN_TIMEFRAME_AS_REPORTED,KEY_MECHANISTIC_QUESTION_TEXT,FUNDING_SOURCE_TEXT,NOTES_INTERNAL_VALIDITY,PDF_SOURCE_IDENTIFIER

McCarthy_1974_JPharmacolExpTher,McCarthy, K.D.,1974,J Pharmacol Exp
Ther,Rabbit,Healthy,InVivo,16,Acetazolamide,
Furosemide,ventriculo-cisternal perfusion
(inulin-dilution),CSF_Production,CSF flow rate,Drug-induced steady state
(60 min),Does furosemide decrease CSF production via carbonic anhydrase
inhibition?,Hoechst Pharmaceutical Co., Lederle Laboratories,Each animal
served as own control.,1-s2.0-S0022356525298226-main.pdf

Maren_1970_JPharmacolExpTher,Maren, T.H.,1970,J Pharmacol Exp
Ther,Cat,Healthy,InVivo,9,Acetazolamide,ventriculo-cisternal perfusion
(inulin dilution),CSF_Production; IonTransport,CSF formation rate; Rate
of entry of total C14O2; Rate of entry of Cl36,Continuous,2 hours
post-drug,Are both HCO3- and Cl- accumulated in CSF through the action
of carbonic anhydrase?,National Institutes of Health Grants NB-01297,
GM-01764 and GM-16934,Small N (3 per group for CSF production).
Artificially ventilated.,1-s2.0-S0022356525285032-main.pdf

Uldall_2017_NeurosciLett,Uldall, M.,2017,Neuroscience
Letters,Rat,Healthy,Mixed,15,Acetazolamide,Epidural ICP recording; in
vitro Na/K ATPase activity assay,ICP; TransporterActivity,ICP; Na/K
ATPase activity,Continuous,60 min post dosing (ICP); 30 min (in vitro
activity),What is the effect of acetazolamide on ICP and the Na/K ATPase
and AQP expression/activity in choroid plexus?,University of Copenhagen,
The A.P Møller Foundation for the Advancement of Medical Science,Small N
(6 per group) for in vivo.,185499353.pdf

Westgate_2023_BrJPharmacol,Westgate, C.S.J.,2023,Br J
Pharmacol,Rat,Healthy,Mixed,NR,Acetazolamide, Topiramate,Telemetric ICP;
in vitro CP secretion model; Na+/K+-ATPase activity assay,ICP;
CSF_Production; TransporterActivity,ICP; CP secretion; \$Na+/K+\$-ATPase
activity,Continuous,24h (telemetry); 30 min (in vitro),Do acetazolamide
and topiramate lower ICP via different mechanisms of action?,Medical
Research Council, NIHR,Robust study, multiple methods, vehicle
controls.,British J Pharmacology - 2023 - Westgate - Acetazolamide and
topiramate lower intracranial pressure through differential.pdf

Bothwell_2021_BrainSci,Bothwell, S.W.,2021,Brain
Sci,Rat,Healthy,InVivo,19,Bumetanide, RN1734,ventriculo-cisternal
perfusion (FITC-inulin),CSF_Production,CSF secretion
rate,Continuous,60--120 min after drug,Is CSF secretion altered by NKCC1
or TRPV4 antagonism in healthy rats?,Hunter Medical Research Institute,
University of Newcastle,Vehicle controlled, anaesthetized
model.,brainsci-11-01117-v2.pdf

Botfield_2017_SciTranslMed,Botfield, H.F.,2017,Sci Transl
Med,Rat,HydrocephalusModel; Healthy,Mixed,NR,Exendin-4
(GLP-1RA),Telemetric ICP; in vitro Na+/K+-ATPase activity,ICP;
TransporterActivity,Intracranial pressure (ICP); Na+/K+-ATPase
activity,Continuous,24h post-injection,Does a GLP-1 receptor agonist
reduce intracranial pressure?,MRC, NIHR,Vehicle controlled, multiple
models (healthy and hydrocephalus).,eb-17-125.pdf

Melby_1982_CanJPhysiolPharmacol,Melby, J.M.,1982,Can J Physiol
Pharmacol,Cat,Healthy,ExVivo,20,Acetazolamide, Furosemide,Isolated
choroid plexus perfusion,CSF_Production,CSF production
rate,Continuous,Steady-state perfusion,What is the effect of
acetazolamide and furosemide on the production and composition of CSF
from the isolated cat choroid plexus?,USPHS, National Institute of
Neurological and Communicative Disorders and Stroke,Isolated ex vivo
prep, own controls.,melby1982.pdf

Pollay_1985_JPhysiol,Pollay, M.,1985,J
Physiol,Rabbit,Healthy,ExVivo,NR,Ouabain, Acetazolamide,
Furosemide,Isolated choroid plexus perfusion,CSF_Production;
TransporterActivity,CSF production; Na,K-ATPase
activity,Continuous,Steady-state perfusion,What is the role of
Na,K-ATPase in the production of CSF?,US Public Health Service
grant,Isolated ex vivo prep.,jphysiol01358-0114.pdf

Barbuskaite_2016_FluidsBarriersCNS,Barbuskaite, D.,2016,Fluids Barriers
CNS,Mouse,Healthy,ExVivo,NR,Acetazolamide, Bumetanide,Calcein
fluorescence (cell volume),CellVolume; TransporterActivity,Choroid
plexus epithelial cell volume,Continuous,60-180s exposure,Do
acetazolamide and bumetanide affect choroid plexus cell volume, and is
this via NKCC1?,Novo Nordisk Foundation, Lundbeck Foundation, Danish
Council for Independent Research,Ex vivo tissue prep, fluorescence
imaging.,s12987-016-0025-2.pdf

Gregoriades_2019_AmJPhysiolCellPhysiol,Gregoriades, J.M.C.,2019,Am J
Physiol Cell Physiol,Mouse,Healthy,Mixed,NR,Bumetanide,Ion-sensitive
microelectrodes; cell volume imaging,TransporterActivity;
CellVolume,NKCC1 activity; CPEC volume,Continuous,Steady state /
minutes,What is the physiological function of the apical Na+-K+-2Cl-
cotransporter 1 (NKCC1) in choroid plexus epithelial cells?,NIH grants,
CONACYT,Genetic KO model (NKCC1-/-), multiple robust
methods.,nihms666090.pdf

Maren_1960_BullJohnsHopkinsHosp,Maren, T.H.,1960,Bull Johns Hopkins
Hosp,Dog,Healthy;
HydrocephalusModel,InVivo,NR,Acetazolamide,Ventriculo-cisternal
perfusion; CSF collection,CSF_Production; IonTransport,CSF flow; Na+
entry,Continuous,Steady state,Review and analysis of acetazolamide
pharmacology related to CSF and hydrocephalus.,NR,Review/analysis paper,
not a single primary study.,v084p00068.pdf

Vogh_1985_CanJPhysiolPharmacol,Vogh, B.P.,1985,Can J Physiol
Pharmacol,Cat; Rat,Healthy,InVivo,NR,Acetazolamide,
Timolol,ventriculo-cisternal perfusion
(14C-inulin),CSF_Production,Formation of CSF,Continuous,90-180 min after
drug,Does timolol plus acetazolamide have an additive effect on CSF
formation?,USPHS grant EY-02340,Anesthetized model.,vogh1985.pdf

Tschirgi_1954_ProcSocExpBiolMed,Tschirgi, R.D.,1954,Proc Soc Exp Biol
Med,Rabbit,Healthy,InVivo,13,Acetazolamide (Diamox),CSF pressure
measurement (cisterna magna),ICP,CSF pressure,Continuous,30-180 min
post-drug,Does a carbonic anhydrase inhibitor (Diamox) inhibit CSF
formation, as measured by CSF pressure?,NR,Small N, anesthetized,
indirect measure of formation.,tschirgi1954.pdf

Code snippet

STUDY_ID,CONDITION_ID,CONDITION_LABEL_AS_REPORTED,IS_CONTROL_OR_REFERENCE,CAI_PRESENT,CAI_DRUG_NAME,CAI_REGIMEN_TEXT,OTHER_DRUGS_OR_GENETICS_TEXT,N_UNITS_IN_CONDITION,PREPARATION_STATE_TEXT,MODEL_STATE_TEXT,CONDITION_NOTES

McCarthy_1974_JPharmacolExpTher,Control,Control flow
period,Yes,No,None,None,None,NR,anesthetized (sodium pentobarbital),
artificially ventilated,Healthy,Each animal served as its own control.

McCarthy_1974_JPharmacolExpTher,ACZ_Doses,Acetazolamide,No,Yes,Acetazolamide,Doses
from 3.0x10\^-6 to 6.0x10\^-4 mol/kg IV,None,8,anesthetized (sodium
pentobarbital), artificially ventilated,Healthy,Dose-effect curve
generated.

McCarthy_1974_JPharmacolExpTher,Furosemide_Doses,Furosemide,No,Yes,Furosemide,Doses
from 2.0x10\^-5 to 3.0x10\^-4 mol/kg IV,None,8,anesthetized (sodium
pentobarbital), artificially ventilated,Healthy,Dose-effect curve
generated.

Maren_1970_JPharmacolExpTher,Control_CSF,Control
(Saline),Yes,No,None,Saline IV,None,3,anesthetized (pentobarbital),
artificially ventilated,Healthy,Control for CSF formation rate.

Maren_1970_JPharmacolExpTher,ACZ_CSF,Acetazolamide,No,Yes,Acetazolamide,50
mg/kg i.v.,None,3,anesthetized (pentobarbital), artificially
ventilated,Healthy,For CSF formation rate.

Maren_1970_JPharmacolExpTher,Control_C14O2,Control
(C14O2),Yes,No,None,None,NaHC14O3 (20 uc/kg) i.v.,4,anesthetized
(pentobarbital), artificially ventilated,Healthy,For C14O2 entry.

Maren_1970_JPharmacolExpTher,ACZ_C14O2,Acetazolamide
(C14O2),No,Yes,Acetazolamide,50 mg/kg i.v. (30 min before
isotope),NaHC14O3 (20 uc/kg) i.v.,3,anesthetized (pentobarbital),
artificially ventilated,Healthy,For C14O2 entry.

Maren_1970_JPharmacolExpTher,Control_Cl36,Control
(Cl36),Yes,No,None,None,NaCl36 (3 uc/kg) i.v.,3,anesthetized
(pentobarbital), artificially ventilated,Healthy,For Cl36 entry.

Maren_1970_JPharmacolExpTher,ACZ_Cl36,Acetazolamide
(Cl36),No,Yes,Acetazolamide,50 mg/kg i.v. (30 min before isotope),NaCl36
(3 uc/kg) i.v.,3,anesthetized (pentobarbital), artificially
ventilated,Healthy,For Cl36 entry.

Uldall_2017_NeurosciLett,Vehicle_ICP,Vehicle,Yes,No,None,sterile saline
i.p.,None,6,anesthetized (Hypnorm/midazolam),Healthy,Main experiment.

Uldall_2017_NeurosciLett,ACZ_ICP,Acetazolamide,No,Yes,Acetazolamide,200
mg i.p.,None,6,anesthetized (Hypnorm/midazolam),Healthy,Main experiment.

Uldall_2017_NeurosciLett,Vehicle_Activity,Vehicle (in
vitro),Yes,No,None,saline,1mM ouabain (for total activity
definition),6,Primary CP epithelial cells,In vitro,Na/K ATPase activity
assay.

Uldall_2017_NeurosciLett,ACZ_Activity,Acetazolamide (in
vitro),No,Yes,Acetazolamide,100 µM for 30 min,1mM ouabain (for total
activity definition),6,Primary CP epithelial cells,In vitro,Na/K ATPase
activity assay.

Westgate_2023_BrJPharmacol,Vehicle_ICP,Vehicle (ICP),Yes,No,None,4% NaCl
(1.25 mL/kg, i.p.),None,6-8,Freely moving (telemetry),Healthy,ICP
telemetry study.

Westgate_2023_BrJPharmacol,ACZ_ICP,Acetazolamide
(ICP),No,Yes,Acetazolamide,103.3 mg/kg i.p.,None,6-8,Freely moving
(telemetry),Healthy,ICP telemetry study.

Westgate_2023_BrJPharmacol,TPM_ICP,Topiramate
(ICP),No,Yes,Topiramate,50.9 mg/kg i.p.,None,6-8,Freely moving
(telemetry),Healthy,ICP telemetry study.

Westgate_2023_BrJPharmacol,Vehicle_Activity,Vehicle (in
vitro),Yes,No,None,Vehicle (0.1% DMSO),Ouabain (1 mM),NR,Primary rat CP
epithelial cells,In vitro,Na+/K+-ATPase activity assay.

Westgate_2023_BrJPharmacol,ACZ_Activity,Acetazolamide (in
vitro),No,Yes,Acetazolamide,100 μM,Ouabain (1 mM),NR,Primary rat CP
epithelial cells,In vitro,Na+/K+-ATPase activity assay.

Westgate_2023_BrJPharmacol,TPM_Activity,Topiramate (in
vitro),No,Yes,Topiramate,100 μM,Ouabain (1 mM),NR,Primary rat CP
epithelial cells,In vitro,Na+/K+-ATPase activity assay.

Bothwell_2021_BrainSci,Vehicle,Vehicle,Yes,No,None,2% DMSO in 0.9%
saline i.p.,None,6,anaesthetized (urethane/pentobarbitone),Healthy,NR

Bothwell_2021_BrainSci,RN1734,RN1734,No,No,None,10 mg/kg i.p.,RN1734
(TRPV4 antagonist),7,anaesthetized (urethane/pentobarbitone),Healthy,NR

Bothwell_2021_BrainSci,Bumetanide,Bumetanide,No,No,None,10 mg/kg
i.p.,Bumetanide (NKCC1 inhibitor),6,anaesthetized
(urethane/pentobarbitone),Healthy,NR

Botfield_2017_SciTranslMed,Vehicle_Healthy,Vehicle (healthy
rat),Yes,No,None,Saline (s.c.),None,6,Freely moving
(telemetry),Healthy,ICP in healthy rats.

Botfield_2017_SciTranslMed,Exendin4_Healthy,Exendin-4 (healthy
rat),No,No,None,2.4 ug/kg s.c.,Exendin-4 (GLP-1RA),6,Freely moving
(telemetry),Healthy,ICP in healthy rats.

Botfield_2017_SciTranslMed,Vehicle_Hydro,Vehicle (HTx
rat),Yes,No,None,Saline (s.c.),None,10,Freely moving
(telemetry),HydrocephalusModel (HTx rat),ICP in hydrocephalus model.

Botfield_2017_SciTranslMed,Exendin4_Hydro,Exendin-4 (HTx
rat),No,No,None,2.4 ug/kg s.c.,Exendin-4 (GLP-1RA),10,Freely moving
(telemetry),HydrocephalusModel (HTx rat),ICP in hydrocephalus model.

Botfield_2017_SciTranslMed,Vehicle_Activity,Vehicle (in
vitro),Yes,No,None,Vehicle,Ouabain,8,Cultured rat choroid plexus
epithelial cells,In vitro,Na+/K+-ATPase activity assay.

Botfield_2017_SciTranslMed,Exendin4_Activity,Exendin-4 (in
vitro),No,No,None,100 nM Exendin-4,Ouabain,8,Cultured rat choroid plexus
epithelial cells,In vitro,Na+/K+-ATPase activity assay.

Melby_1982_CanJPhysiolPharmacol,Control,Control,Yes,No,None,None,None,20,Isolated
perfused choroid plexus,Healthy,Control period for each animal.

Melby_1982_CanJPhysiolPharmacol,ACZ_low,Acetazolamide 10\^-5
M,No,Yes,Acetazolamide,1 x 10\^-5 M in perfusate,None,6,Isolated
perfused choroid plexus,Healthy,NR

Melby_1982_CanJPhysiolPharmacol,ACZ_high,Acetazolamide 10\^-4
M,No,Yes,Acetazolamide,1 x 10\^-4 M in perfusate,None,7,Isolated
perfused choroid plexus,Healthy,NR

Melby_1982_CanJPhysiolPharmacol,Furosemide_low,Furosemide 10\^-5
M,No,Yes,Furosemide,1 x 10\^-5 M in perfusate,None,7,Isolated perfused
choroid plexus,Healthy,NR

Melby_1982_CanJPhysiolPharmacol,Furosemide_high,Furosemide 10\^-4
M,No,Yes,Furosemide,1 x 10\^-4 M in perfusate,None,6,Isolated perfused
choroid plexus,Healthy,NR

Pollay_1985_JPhysiol,Control,Control,Yes,No,None,None,None,12,Isolated
perfused choroid plexus,Healthy,Table 1 data.

Pollay_1985_JPhysiol,Ouabain_10-4,Ouabain 10-4 M,No,No,None,10\^-4 M
Ouabain in perfusate,Ouabain,5,Isolated perfused choroid
plexus,Healthy,Table 1 data.

Pollay_1985_JPhysiol,Ouabain_10-3,Ouabain 10-3 M,No,No,None,10\^-3 M
Ouabain in perfusate,Ouabain,5,Isolated perfused choroid
plexus,Healthy,Table 1 data.

Pollay_1985_JPhysiol,ACZ_10-4,Acetazolamide 10-4
M,No,Yes,Acetazolamide,10\^-4 M Acetazolamide in
perfusate,None,5,Isolated perfused choroid plexus,Healthy,Table 1 data.

Pollay_1985_JPhysiol,Furosemide_10-3,Furosemide 10-3
M,No,Yes,Furosemide,10\^-3 M Furosemide in perfusate,None,5,Isolated
perfused choroid plexus,Healthy,Table 1 data.

Barbuskaite_2016_FluidsBarriersCNS,Control,Control,Yes,No,None,Isotonic
solution,None,18,Acutely isolated choroid plexus (4th
vent.),Healthy,Cell volume imaging.

Barbuskaite_2016_FluidsBarriersCNS,ACZ_1mM,Acetazolamide 1
mM,No,Yes,Acetazolamide,1 mM Acetazolamide,None,12,Acutely isolated
choroid plexus (4th vent.),Healthy,Cell volume imaging.

Barbuskaite_2016_FluidsBarriersCNS,Bumetanide_10uM,Bumetanide 10
μM,No,No,None,10 μM Bumetanide,Bumetanide (NKCC1 inhibitor),10,Acutely
isolated choroid plexus (4th vent.),Healthy,Cell volume imaging.

Barbuskaite_2016_FluidsBarriersCNS,ACZ_Bumetanide,ACZ +
Bumetanide,No,Yes,Acetazolamide,1 mM ACZ + 10 μM Bumetanide,Bumetanide
(NKCC1 inhibitor),11,Acutely isolated choroid plexus (4th
vent.),Healthy,Cell volume imaging.

Gregoriades_2019_AmJPhysiolCellPhysiol,WT_Control,Wild-type
(control),Yes,No,None,Control solution,None,NR,Isolated CP epithelial
cells,Healthy,CPEC volume regulation.

Gregoriades_2019_AmJPhysiolCellPhysiol,WT_Bumetanide,Wild-type +
Bumetanide,No,No,None,50 μM bumetanide,Bumetanide (NKCC1
inhibitor),NR,Isolated CP epithelial cells,Healthy,CPEC volume
regulation.

Gregoriades_2019_AmJPhysiolCellPhysiol,NKCC1_KO,NKCC1-KO,No,No,None,Control
solution,NKCC1-/-,NR,Isolated CP epithelial cells,Healthy,CPEC volume
regulation.

Maren_1960_BullJohnsHopkinsHosp,Control,Control,Yes,No,None,None,None,4,Anesthetized
dog,Healthy,CSF flow (Davson).

Maren_1960_BullJohnsHopkinsHosp,ACZ_50mgkg,Acetazolamide,No,Yes,Acetazolamide,50
mg/kg,None,4,Anesthetized dog,Healthy,CSF flow (Davson).

Maren_1960_BullJohnsHopkinsHosp,Control_Na,Control (Na+
entry),Yes,No,None,None,24Na,NR,Anesthetized dog,Healthy,Na+ entry
(Sweet et al.).

Maren_1960_BullJohnsHopkinsHosp,ACZ_Na,Acetazolamide (Na+
entry),No,Yes,Acetazolamide,50-100 mg/kg,24Na,NR,Anesthetized
dog,Healthy,Na+ entry (Sweet et al.).

Vogh_1985_CanJPhysiolPharmacol,Control_Cat,Control
(cat),Yes,No,None,Saline i.v.,None,6,anaesthetized
(pentobarbital),Healthy,Cat study.

Vogh_1985_CanJPhysiolPharmacol,ACZ_Cat,Acetazolamide
(cat),No,Yes,Acetazolamide,5 mg/kg i.v.,None,6,anaesthetized
(pentobarbital),Healthy,Cat study.

Vogh_1985_CanJPhysiolPharmacol,Timolol_Cat,Timolol (cat),No,No,None,0.5
mg/kg i.v.,Timolol,6,anaesthetized (pentobarbital),Healthy,Cat study.

Vogh_1985_CanJPhysiolPharmacol,Combo_Cat,Timolol + Acetazolamide
(cat),No,Yes,Acetazolamide,0.5 mg/kg Timolol + 5 mg/kg ACZ
i.v.,Timolol,6,anaesthetized (pentobarbital),Healthy,Cat study.

Vogh_1985_CanJPhysiolPharmacol,Control_Rat,Control
(rat),Yes,No,None,Saline i.v.,None,12,anaesthetized
(pentobarbital),Healthy,Rat study.

Vogh_1985_CanJPhysiolPharmacol,ACZ_Rat,Acetazolamide
(rat),No,Yes,Acetazolamide,5 mg/kg i.v.,None,9,anaesthetized
(pentobarbital),Healthy,Rat study.

Tschirgi_1954_ProcSocExpBiolMed,Control,Control,Yes,No,None,None,None,13,Anesthetized
(Dial-Urethane),Healthy,Baseline pressure for each animal.

Tschirgi_1954_ProcSocExpBiolMed,ACZ_50mgkg,Diamox 50
mg/kg,No,Yes,Acetazolamide,50 mg/kg i.v.,None,7,Anesthetized
(Dial-Urethane),Healthy,NR

Tschirgi_1954_ProcSocExpBiolMed,ACZ_100mgkg,Diamox 100
mg/kg,No,Yes,Acetazolamide,100 mg/kg i.v.,None,6,Anesthetized
(Dial-Urethane),Healthy,NR

Code snippet

STUDY_ID,ROW_TYPE,CONDITION_ID,CONDITION_ID_REFERENCE,CONDITION_ID_EXPERIMENTAL,MEASUREMENT_DOMAIN,MEASUREMENT_NAME_STANDARDIZED,MEASUREMENT_NAME_AS_REPORTED,MEASUREMENT_DEFINITION_TEXT,TIMEPOINT_OR_WINDOW_TEXT,CENTRAL_TENDENCY_TYPE,CENTRAL_VALUE,SPREAD_TYPE,SPREAD_VALUE_1,SPREAD_VALUE_2,N_MEASURED,EFFECT_MEASURE_TYPE,EFFECT_VALUE,EFFECT_P_VALUE,UNITS,MEASUREMENT_SOURCE_LOCATION,MEASUREMENT_NOTES

\[cite_start\]McCarthy_1974_JPharmacolExpTher,ContrastEffect,NA,Control,ACZ_Doses,CSF_Production,CSF_FormationRate_MaxInhibition,Maximal
reduction in CSF flow,Max reduction vs control flow,Drug-induced steady
state,Mean,50-60,Range,NR,NA,8,PercentChange,50-60,NR,%,Abstract\[cite:
3859\],Range 50-60%

\[cite_start\]McCarthy_1974_JPharmacolExpTher,ContrastEffect,NA,Control,Furosemide_Doses,CSF_Production,CSF_FormationRate_MaxInhibition,Maximal
reduction in CSF flow,Max reduction vs control flow,Drug-induced steady
state,Mean,50-60,Range,NR,NA,8,PercentChange,50-60,NR,%,Abstract\[cite:
3859\],Range 50-60%

\[cite_start\]McCarthy_1974_JPharmacolExpTher,ContrastEffect,NA,Control,ACZ_ED50,CSF_Production,CSF_FormationRate_Inhibition_ED50,ED50
of acetazolamide to reduce CSF flow rate,% of Max Effect,Drug-induced
steady state,Mean,3.0E-05,NR,NR,NA,8,Other,50,NR,mol/kg,Fig 2a / text
p.197 \[cite: 3976\]

\[cite_start\]McCarthy_1974_JPharmacolExpTher,ContrastEffect,NA,Control,Furosemide_ED50,CSF_Production,CSF_FormationRate_Inhibition_ED50,ED50
of furosemide to reduce flow rate,% of Max Effect,Drug-induced steady
state,Mean,8.0E-05,NR,NR,NA,8,Other,50,NR,mol/kg,Fig 2b / text p.197
\[cite: 3978\]

\[cite_start\]McCarthy_1974_JPharmacolExpTher,ConditionValue,ACZ_ED50,NA,NA,Other,CA_Inhibition,Choroid
plexus carbonic anhydrase inhibition (%) in vivo,% inhibition at ED50
dose,Drug-induced steady state,Mean,99.9,NR,NR,NA,NR,NA,NA,NR,%,text
p.197 \[cite: 3976\]

\[cite_start\]McCarthy_1974_JPharmacolExpTher,ConditionValue,Furosemide_ED50,NA,NA,Other,CA_Inhibition,Choroid
plexus carbonic anhydrase inhibition (%) in vivo,% inhibition at ED50
dose,Drug-induced steady state,Mean,98.7,NR,NR,NA,NR,NA,NA,NR,%,text
p.197 \[cite: 3979\]

\[cite_start\]McCarthy_1974_JPharmacolExpTher,ContrastEffect,NA,Control,ACZ_Doses,Other,CA_Inhibition_Threshold,%
CA inhibition before CSF flow decrease,Inhibition of CA in choroid
plexus,Drug-induced steady
state,Mean,\>99.5,NR,NR,NA,8,Other,NA,NR,%,text p.197 \[cite: 3975\]

\[cite_start\]McCarthy_1974_JPharmacolExpTher,ContrastEffect,NA,Control,Furosemide_Doses,Other,CA_Inhibition_Threshold,%
CA inhibition at significant CSF flow decrease,Inhibition of CA in
choroid plexus,Drug-induced steady
state,Mean,96-97,Range,NR,NA,8,Other,NA,NR,%,text p.199\[cite:
4070\],Range 96-97%

\[cite_start\]McCarthy_1974_JPharmacolExpTher,ConditionValue,NR,NA,NA,Other,CA_Concentration,Concentration
of carbonic anhydrase in the choroid plexus,In vitro inhibition
studies,NR,Mean,8.45E-06,NR,NR,NA,NR,NA,NA,NR,M,text p.196 \[cite:
3930\]

\[cite_start\]McCarthy_1974_JPharmacolExpTher,ConditionValue,NR,NA,NA,Other,ACZ_KI,K(I)
of acetazolamide,In vitro
studies,NR,Mean,1.95E-08,NR,NR,NA,NR,NA,NA,NR,M,text p.196 \[cite:
3931\]

\[cite_start\]McCarthy_1974_JPharmacolExpTher,ConditionValue,NR,NA,NA,Other,Furosemide_KI,K(I)
of furosemide,In vitro
studies,NR,Mean,2.33E-06,NR,NR,NA,NR,NA,NA,NR,M,text p.196 \[cite:
3931\]

\[cite_start\]Maren_1970_JPharmacolExpTher,ConditionValue,Control_CSF,NA,NA,CSF_Production,CSF_FormationRate,CSF
formation rate,ventriculo-cisternal perfusion,Control period (2
hours),Mean,25,SE,4,3,NA,NA,NR,μl/min,Table 1 \[cite: 4235\]

\[cite_start\]Maren_1970_JPharmacolExpTher,ConditionValue,ACZ_CSF,NA,NA,CSF_Production,CSF_FormationRate,CSF
formation rate,ventriculo-cisternal perfusion,30-45 min after
injection,Mean,14,SE,4,3,NA,NA,NR,μl/min,Table 1 \[cite: 4235\]

\[cite_start\]Maren_1970_JPharmacolExpTher,ContrastEffect,NA,Control_CSF,ACZ_CSF,CSF_Production,CSF_FormationRate_Inhibition,%
change from control,ventriculo-cisternal perfusion,30-45 min after
injection,Mean,-45,SE,7.5,3,PercentChange,-45,NR,%,Table 1 \[cite:
4235\]

\[cite_start\]Maren_1970_JPharmacolExpTher,ContrastEffect,NA,Control_C14O2,ACZ_C14O2,IonTransport,C14O2_Entry_Rate,Difference
between control and inhibited rates (initial),Rate of entry of total
C14O2 into CSF perfusate,Initial rates
post-isotope,Mean,5,NR,NR,NA,3-4,Ratio,5,NR,fold,text p.199 \[cite:
4248\]

\[cite_start\]Maren_1970_JPharmacolExpTher,ConditionValue,Control_Cl36,NA,NA,IonTransport,Cl36_Entry_Rate,Rate
of entry of Cl36 into the CSF perfusate,Steady
state,Mean,6,NR,NR,NA,3,NA,NA,NR,concentration units/min,text p.200
\[cite: 4317\]

\[cite_start\]Maren_1970_JPharmacolExpTher,ConditionValue,ACZ_Cl36,NA,NA,IonTransport,Cl36_Entry_Rate,Rate
of entry of Cl36 into the CSF perfusate,Steady
state,Mean,3.3,NR,NR,NA,3,NA,NA,NR,concentration units/min,text p.200
\[cite: 4318\]

\[cite_start\]Maren_1970_JPharmacolExpTher,ContrastEffect,NA,Control_Cl36,ACZ_Cl36,IonTransport,Cl36_Entry_Rate_Inhibition,Decrease
from control,Rate of entry of Cl36,Steady
state,Mean,-45,NR,NR,NA,3,PercentChange,-45,NR,%,text p.200 \[cite:
4318\]

\[cite_start\]Uldall_2017_NeurosciLett,ContrastEffect,NA,Vehicle_ICP,ACZ_ICP,ICP,ICP_Mean_Reduction,Percentage
change from baseline,Epidural ICP recording,10 min
post-injection,Mean,18,SE,5,6,PercentChange,18,P\<0.05,%,text p.13
\[cite: 506\]

\[cite_start\]Uldall_2017_NeurosciLett,ContrastEffect,NA,Vehicle_ICP,ACZ_ICP,ICP,ICP_Mean_Reduction_Max,Percentage
change from baseline,Epidural ICP recording,55 min
post-injection,Mean,66,SE,4,6,PercentChange,66,P\<0.00001,%,text p.13 /
Fig 1B \[cite: 506\]

\[cite_start\]Uldall_2017_NeurosciLett,ConditionValue,Vehicle_Activity,NA,NA,TransporterActivity,NaK_ATPase_Activity,Phophate
produced by the Na/K ATPase in %,Colorimetric assay
(Ouabain-sensitive),30 min incubation,Mean,47,SE,6,6,NA,NA,NR,%,Fig 2 /
text p.14 \[cite: 514\]

\[cite_start\]Uldall_2017_NeurosciLett,ConditionValue,ACZ_Activity,NA,NA,TransporterActivity,NaK_ATPase_Activity,Phophate
produced by the Na/K ATPase in %,Colorimetric assay
(Ouabain-sensitive),30 min incubation,Mean,16,SE,3,6,NA,NA,NR,%,Fig 2 /
text p.14 \[cite: 514\]

\[cite_start\]Uldall_2017_NeurosciLett,ContrastEffect,NA,Vehicle_Activity,ACZ_Activity,TransporterActivity,NaK_ATPase_Activity_Inhibition,Na/K
ATPase activity vs control,Colorimetric assay (Ouabain-sensitive),30 min
incubation,Mean,NR,NR,6,Other,NR,P=0.0022,%,text p.14 \[cite: 515\]

\[cite_start\]Uldall_2017_NeurosciLett,ContrastEffect,NA,Vehicle_ICP,ACZ_ICP,GeneExpression,AQP1_mRNA,AQP1
mRNA, whole tissue,qPCR on CP tissue,1.5h
post-dose,Mean,NR,NR,6,Other,NA,P=0.699,Normalized Copy Number,Fig 3A
\[cite: 522\]

\[cite_start\]Uldall_2017_NeurosciLett,ContrastEffect,NA,Vehicle_ICP,ACZ_ICP,GeneExpression,AQP4_mRNA,AQP4
mRNA, whole tissue,qPCR on CP tissue,1.5h
post-dose,Mean,NR,NR,6,Other,NA,P=0.421,Normalized Copy Number,Fig 3B
\[cite: 522\]

\[cite_start\]Uldall_2017_NeurosciLett,ContrastEffect,NA,Vehicle_ICP,ACZ_ICP,GeneExpression,NaK_ATPase_mRNA,Na/K
ATPase alfa1 mRNA, whole tissue,qPCR on CP tissue,1.5h
post-dose,Mean,NR,NR,6,Other,NA,P=0.937,Normalized Copy Number,Fig 3C
\[cite: 522\]

\[cite_start\]Uldall_2017_NeurosciLett,ContrastEffect,NA,Vehicle_ICP,ACZ_ICP,Other,AQP1_Protein_Membrane,AQP1
protein in membrane fraction,Western blot on CP membrane fraction,1.5h
post-dose,Mean,NR,NR,6,Other,NA,P=0.0152,Normalized ratio,Fig 4A \[cite:
528\]

\[cite_start\]Uldall_2017_NeurosciLett,ContrastEffect,NA,Vehicle_ICP,ACZ_ICP,TransporterActivity,NaK_ATPase_Protein_Membrane,Na/K
ATPase protein in membrane fraction,Western blot on CP membrane
fraction,1.5h post-dose,Mean,NR,NR,6,Other,NA,P=0.0411,Normalized
ratio,Fig 4B \[cite: 528\]

Westgate_2023_BrJPharmacol,ContrastEffect,NA,Vehicle_ICP,ACZ_ICP,ICP,ICP_Mean_Reduction,Change
in ICP (mmHg) from baseline,Telemetric ICP,30 min
post-injection,Mean,0.4,SE,0.6,6-8,MD,0.4,P \> 0.9999,mmHg,Figure 1d

Westgate_2023_BrJPharmacol,ContrastEffect,NA,Vehicle_ICP,TPM_ICP,ICP,ICP_Mean_Reduction,Change
in ICP (mmHg) from baseline,Telemetric ICP,30 min
post-injection,Mean,-1.8,SE,0.7,6-8,MD,-1.8,P = 0.0469,mmHg,Figure 1d

Westgate_2023_BrJPharmacol,ConditionValue,Vehicle_Activity,NA,NA,TransporterActivity,NaK_ATPase_Activity,Ouabain-sensitive
\$Na+/K+\$-ATPase activity,colorimetric phosphate assay,30 min
incubation,Mean,47.4,SE,5.7,6,NA,NA,NR,% of total ATPase activity,Figure
2a

Westgate_2023_BrJPharmacol,ConditionValue,ACZ_Activity,NA,NA,TransporterActivity,NaK_ATPase_Activity,Ouabain-sensitive
\$Na+/K+\$-ATPase activity,colorimetric phosphate assay,30 min
incubation,Mean,16.4,SE,3.4,6,NA,NA,NR,% of total ATPase activity,Figure
2a

Westgate_2023_BrJPharmacol,ConditionValue,TPM_Activity,NA,NA,TransporterActivity,NaK_ATPase_Activity,Ouabain-sensitive
\$Na+/K+\$-ATPase activity,colorimetric phosphate assay,30 min
incubation,Mean,44.5,SE,3.8,6,NA,NA,NR,% of total ATPase activity,Figure
2a

Westgate_2023_BrJPharmacol,ContrastEffect,NA,Vehicle_Activity,ACZ_Activity,TransporterActivity,NaK_ATPase_Activity,Ouabain-sensitive
\$Na+/K+\$-ATPase activity vs Vehicle,colorimetric phosphate assay,30
min incubation,Mean,NR,NR,6,Other,NR,P \< 0.001,%,Figure 2a

Westgate_2023_BrJPharmacol,ContrastEffect,NA,Vehicle_Activity,TPM_Activity,TransporterActivity,NaK_ATPase_Activity,Ouabain-sensitive
\$Na+/K+\$-ATPase activity vs Vehicle,colorimetric phosphate assay,30
min incubation,Mean,NR,NR,6,Other,NR,P \> 0.9999,%,Figure 2a

Westgate_2023_BrJPharmacol,ConditionValue,Vehicle_Secretion,NA,NA,CSF_Production,CP_Secretion_Rate,CP
secretion rate,in vitro CP secretion
model,NR,Mean,0.44,SE,0.05,7,NA,NA,NR,μl/mg/h,Figure 2b

Westgate_2023_BrJPharmacol,ConditionValue,ACZ_Secretion,NA,NA,CSF_Production,CP_Secretion_Rate,CP
secretion rate (100 μM ACZ),in vitro CP secretion
model,NR,Mean,0.17,SE,0.07,7,NA,NA,NR,μl/mg/h,Figure 2b

Westgate_2023_BrJPharmacol,ConditionValue,TPM_Secretion,NA,NA,CSF_Production,CP_Secretion_Rate,CP
secretion rate (100 μM TPM),in vitro CP secretion
model,NR,Mean,0.09,SE,0.05,8,NA,NA,NR,μl/mg/h,Figure 2b

Westgate_2023_BrJPharmacol,ContrastEffect,NA,Vehicle_Secretion,ACZ_Secretion,CSF_Production,CP_Secretion_Rate_Effect,CP
secretion rate (100 μM ACZ) vs Vehicle,in vitro CP secretion
model,NR,Mean,NR,NR,7,Other,NR,P = 0.005,μl/mg/h,Figure 2b

Westgate_2023_BrJPharmacol,ContrastEffect,NA,Vehicle_Secretion,TPM_Secretion,CSF_Production,CP_Secretion_Rate_Effect,CP
secretion rate (100 μM TPM) vs Vehicle,in vitro CP secretion
model,NR,Mean,NR,NR,8,Other,NR,P \< 0.001,μl/mg/h,Figure 2b

Bothwell_2021_BrainSci,ConditionValue,Vehicle,NA,NA,CSF_Production,CSF_SecretionRate,CSF
secretion rate,ventriculo-cisternal perfusion,60-120
min,Mean,2.7,SE,0.4,6,NA,NA,NR,μL/min,Figure 1

Bothwell_2021_BrainSci,ConditionValue,RN1734,NA,NA,CSF_Production,CSF_SecretionRate,CSF
secretion rate,ventriculo-cisternal perfusion,60-120
min,Mean,2.9,SE,0.3,7,NA,NA,NR,μL/min,Figure 1

Bothwell_2021_BrainSci,ConditionValue,Bumetanide,NA,NA,CSF_Production,CSF_SecretionRate,CSF
secretion rate,ventriculo-cisternal perfusion,60-120
min,Mean,2.6,SE,0.3,6,NA,NA,NR,μL/min,Figure 1

Bothwell_2021_BrainSci,ContrastEffect,NA,Vehicle,RN1734,CSF_Production,CSF_SecretionRate_Effect,CSF
secretion rate vs Vehicle,ventriculo-cisternal perfusion,60-120
min,Mean,NR,NR,7,Other,NA,p \> 0.05,μL/min,Figure 1

Bothwell_2021_BrainSci,ContrastEffect,NA,Vehicle,Bumetanide,CSF_Production,CSF_SecretionRate_Effect,CSF
secretion rate vs Vehicle,ventriculo-cisternal perfusion,60-120
min,Mean,NR,NR,6,Other,NA,p \> 0.05,μL/min,Figure 1

Botfield_2017_SciTranslMed,ContrastEffect,NA,Vehicle_Healthy,Exendin4_Healthy,ICP,ICP_Mean_Reduction,ICP
reduction in healthy rats,Telemetric ICP,24 hours
post-injection,Mean,44,SE,5.7,6,PercentChange,44,P \< 0.0001,%,Fig. 3E

Botfield_2017_SciTranslMed,ContrastEffect,NA,Vehicle_Hydro,Exendin4_Hydro,ICP,ICP_Mean_Reduction,ICP
reduction in hydrocephalic rats,Telemetric ICP,24 hours
post-injection,Mean,36.4,SE,11,10,PercentChange,36.4,P = 0.002,%,Fig. 4F

Botfield_2017_SciTranslMed,ContrastEffect,NA,Vehicle_Activity,Exendin4_Activity,TransporterActivity,NaK_ATPase_Activity,Na+/K+-ATPase
activity inhibition by Exendin-4,in vitro assay,30
min,Mean,31,SE,5,8,PercentChange,31,P = 0.0007,%,Fig. 2C

Melby_1982_CanJPhysiolPharmacol,ConditionValue,Control,NA,NA,CSF_Production,CSF_ProductionRate,CSF
production rate,Isolated perfused choroid plexus,Control
period,Mean,7.5,SE,0.4,20,NA,NA,NR,μL/min,Table 1

Melby_1982_CanJPhysiolPharmacol,ContrastEffect,NA,Control,ACZ_low,CSF_Production,CSF_ProductionRate_Inhibition,CSF
production rate (percent of control),Isolated perfused choroid
plexus,Drug period,Mean,73,SE,4,6,PercentChange,-27,P \< 0.01,%,Table 1

Melby_1982_CanJPhysiolPharmacol,ContrastEffect,NA,Control,ACZ_high,CSF_Production,CSF_ProductionRate_Inhibition,CSF
production rate (percent of control),Isolated perfused choroid
plexus,Drug period,Mean,48,SE,4.2,7,PercentChange,-52,P \< 0.001,%,Table
1

Melby_1982_CanJPhysiolPharmacol,ContrastEffect,NA,Control,Furosemide_low,CSF_Production,CSF_ProductionRate_Inhibition,CSF
production rate (percent of control),Isolated perfused choroid
plexus,Drug period,Mean,86,SE,3.8,7,PercentChange,-14,P \< 0.05,%,Table
1

Melby_1982_CanJPhysiolPharmacol,ContrastEffect,NA,Control,Furosemide_high,CSF_Production,CSF_ProductionRate_Inhibition,CSF
production rate (percent of control),Isolated perfused choroid
plexus,Drug period,Mean,66,SE,3.2,6,PercentChange,-34,P \< 0.001,%,Table
1

\[cite_start\]Pollay_1985_JPhysiol,ConditionValue,Control,NA,NA,CSF_Production,CSF_ProductionRate,CSF
production,Isolated perfused choroid
plexus,Control,Mean,7.21,SE,0.44,12,NA,NA,NR,μl/min per plexus,Table 1
\[cite: 7921\]

\[cite_start\]Pollay_1985_JPhysiol,ContrastEffect,NA,Control,Ouabain_10-4,CSF_Production,CSF_ProductionRate_Inhibition,%
Inhibition (CSF production),Isolated perfused choroid
plexus,Drug,Mean,56.5,SE,4.3,5,PercentChange,56.5,P \< 0.01,%,Table 1
\[cite: 7913\]

\[cite_start\]Pollay_1985_JPhysiol,ContrastEffect,NA,Control,Ouabain_10-3,CSF_Production,CSF_ProductionRate_Inhibition,%
Inhibition (CSF production),Isolated perfused choroid
plexus,Drug,Mean,78.5,SE,5.2,5,PercentChange,78.5,P \< 0.01,%,Table 1
\[cite: 7913\]

\[cite_start\]Pollay_1985_JPhysiol,ContrastEffect,NA,Control,ACZ_10-4,CSF_Production,CSF_ProductionRate_Inhibition,%
Inhibition (CSF production),Isolated perfused choroid
plexus,Drug,Mean,54.4,SE,4.8,5,PercentChange,54.4,P \< 0.01,%,Table 1
\[cite: 7913\]

\[cite_start\]Pollay_1985_JPhysiol,ContrastEffect,NA,Control,Furosemide_10-3,CSF_Production,CSF_ProductionRate_Inhibition,%
Inhibition (CSF production),Isolated perfused choroid
plexus,Drug,Mean,41.5,SE,6.1,5,PercentChange,41.5,P \< 0.01,%,Table 1
\[cite: 7913\]

\[cite_start\]Pollay_1985_JPhysiol,ConditionValue,Control,NA,NA,TransporterActivity,NaK_ATPase_Activity,Na,K-ATPase
activity,enzyme assay,Control,Mean,2.76,SE,0.22,10,NA,NA,NR,μM Pi/mg
protein per h,Table 2 \[cite: 7913\]

\[cite_start\]Pollay_1985_JPhysiol,ContrastEffect,NA,Control,Ouabain_10-4,TransporterActivity,NaK_ATPase_Activity_Inhibition,%
Inhibition (Na,K-ATPase activity),enzyme
assay,Drug,Mean,46.4,SE,4.2,5,PercentChange,46.4,P \< 0.01,%,Table 2
\[cite: 7913\]

\[cite_start\]Pollay_1985_JPhysiol,ContrastEffect,NA,Control,ACZ_10-4,TransporterActivity,NaK_ATPase_Activity_Inhibition,%
Inhibition (Na,K-ATPase activity),enzyme
assay,Drug,Mean,4.4,SE,2.1,5,PercentChange,4.4,P \> 0.05,%,Table 2
\[cite: 7913\]

Barbuskaite_2016_FluidsBarriersCNS,ConditionValue,Control,NA,NA,CellVolume,CP_CellVolume_Change,Rate
of swelling,Calcein
fluorescence,60-180s,Mean,0.007,SE,0.001,18,NA,NA,NR,%/s,Figure 2C

Barbuskaite_2016_FluidsBarriersCNS,ConditionValue,ACZ_1mM,NA,NA,CellVolume,CP_CellVolume_Change,Rate
of swelling,Calcein
fluorescence,60-180s,Mean,0,SE,0.001,12,NA,NA,NR,%/s,Figure 2C

Barbuskaite_2016_FluidsBarriersCNS,ConditionValue,Bumetanide_10uM,NA,NA,CellVolume,CP_CellVolume_Change,Rate
of swelling,Calcein
fluorescence,60-180s,Mean,0.007,SE,0.001,10,NA,NA,NR,%/s,Figure 2C

Barbuskaite_2016_FluidsBarriersCNS,ConditionValue,ACZ_Bumetanide,NA,NA,CellVolume,CP_CellVolume_Change,Rate
of swelling,Calcein
fluorescence,60-180s,Mean,0.001,SE,0.001,11,NA,NA,NR,%/s,Figure 2C

Barbuskaite_2016_FluidsBarriersCNS,ContrastEffect,NA,Control,ACZ_1mM,CellVolume,CP_CellVolume_Change_Effect,Rate
of swelling vs Control,Calcein
fluorescence,60-180s,Mean,NR,NR,12,Other,NR,p\<0.01,NR,Figure 2C

Barbuskaite_2016_FluidsBarriersCNS,ContrastEffect,NA,Control,Bumetanide_10uM,CellVolume,CP_CellVolume_Change_Effect,Rate
of swelling vs Control,Calcein
fluorescence,60-180s,Mean,NR,NR,10,Other,NR,p\>0.05,NR,Figure 2C

Barbuskaite_2016_FluidsBarriersCNS,ContrastEffect,NA,Control,ACZ_Bumetanide,CellVolume,CP_CellVolume_Change_Effect,Rate
of swelling vs Control,Calcein
fluorescence,60-180s,Mean,NR,NR,11,Other,NR,p\<0.01,NR,Figure 2C

Barbuskaite_2016_FluidsBarriersCNS,ContrastEffect,NA,ACZ_1mM,ACZ_Bumetanide,CellVolume,CP_CellVolume_Change_Effect,Rate
of swelling (ACZ+Bumet) vs ACZ,Calcein
fluorescence,60-180s,Mean,NR,NR,11,Other,NR,p\>0.05,NR,Figure 2C

Gregoriades_2019_AmJPhysiolCellPhysiol,ConditionValue,WT_Control,NA,NA,CellVolume,CPEC_Volume,Steady-state
cell volume,Calcein
fluorescence,Steady-state,Mean,1,SE,0.01,15,NA,NA,NR,V/V0,Figure 8A

Gregoriades_2019_AmJPhysiolCellPhysiol,ConditionValue,WT_Bumetanide,NA,NA,CellVolume,CPEC_Volume,Steady-state
cell volume,Calcein fluorescence,Steady-state (30
min),Mean,0.9,SE,0.01,13,NA,NA,NR,V/V0,Figure 8A

Gregoriades_2019_AmJPhysiolCellPhysiol,ConditionValue,NKCC1_KO,NA,NA,CellVolume,CPEC_Volume,Steady-state
cell volume,Calcein
fluorescence,Steady-state,Mean,0.92,SE,0.01,12,NA,NA,NR,V/V0,Figure 8A

Gregoriades_2019_AmJPhysiolCellPhysiol,ContrastEffect,NA,WT_Control,WT_Bumetanide,CellVolume,CPEC_Volume_Effect,Steady-state
cell volume vs WT,Calcein fluorescence,Steady-state (30
min),Mean,NR,NR,13,PercentChange,-10,P \< 0.001,V/V0,Figure 8A

Gregoriades_2019_AmJPhysiolCellPhysiol,ContrastEffect,NA,WT_Control,NKCC1_KO,CellVolume,CPEC_Volume_Effect,Steady-state
cell volume vs WT,Calcein
fluorescence,Steady-state,Mean,NR,NR,12,PercentChange,-8,P \<
0.001,V/V0,Figure 8A

\[cite_start\]Maren_1960_BullJohnsHopkinsHosp,ConditionValue,Control,NA,NA,CSF_Production,CSF_Flow,CSF
flow (Davson),V-C perfusion,Steady
state,Mean,0.19,NR,NR,NA,4,NA,NA,NR,ml./min.,Table III \[cite: 5350\]

\[cite_start\]Maren_1960_BullJohnsHopkinsHosp,ConditionValue,ACZ_50mgkg,NA,NA,CSF_Production,CSF_Flow,CSF
flow (Davson),V-C
perfusion,Post-drug,Mean,0.09,NR,NR,NA,4,NA,NA,NR,ml./min.,Table III
\[cite: 5350\]

\[cite_start\]Maren_1960_BullJohnsHopkinsHosp,ContrastEffect,NA,Control,ACZ_50mgkg,CSF_Production,CSF_Flow_Inhibition,%
Inhibition,V-C
perfusion,Post-drug,Mean,53,NR,NR,NA,4,PercentChange,53,NR,%,Table III
\[cite: 5350\]

Maren_1960_BullJohnsHopkinsHosp,ContrastEffect,NA,Control_Na,ACZ_Na,IonTransport,Na_Entry_Inhibition,%
Inhibition of Na+ entry into CSF,24Na
tracer,Post-drug,Mean,60,Range,50-70,NA,NR,PercentChange,60,NR,%,text p.
\[cite_start\]11 \[cite: 5334\]

Maren_1960_BullJohnsHopkinsHosp,ContrastEffect,NA,Control,ACZ_50mgkg,Other,CA_Inhibition,%
Inhibition choroid plexus CA,In vivo
analysis,Post-drug,Mean,99.9,NR,NR,NA,NR,PercentChange,99.9,NR,%,text p.
\[cite_start\]18 \[cite: 5339\]

\[cite_start\]Vogh_1985_CanJPhysiolPharmacol,ConditionValue,Control_Cat,NA,NA,CSF_Production,CSF_FormationRate,Rate
of formation of CSF (cat),V-C perfusion,90-180
min,Mean,21.6,SE,1.2,6,NA,NA,NR,μL/min,Table 1 \[cite: 7750\]

\[cite_start\]Vogh_1985_CanJPhysiolPharmacol,ContrastEffect,NA,Control_Cat,ACZ_Cat,CSF_Production,CSF_FormationRate_Inhibition,%
decrease from control (cat),V-C perfusion,90-180
min,Mean,56,SE,5,6,PercentChange,-56,P \< 0.01,%,Table 1 \[cite: 7750\]

\[cite_start\]Vogh_1985_CanJPhysiolPharmacol,ContrastEffect,NA,Control_Cat,Timolol_Cat,CSF_Production,CSF_FormationRate_Inhibition,%
decrease from control (cat),V-C perfusion,90-180
min,Mean,31,SE,3,6,PercentChange,-31,P \< 0.01,%,Table 1 \[cite: 7750\]

\[cite_start\]Vogh_1985_CanJPhysiolPharmacol,ContrastEffect,NA,Control_Cat,Combo_Cat,CSF_Production,CSF_FormationRate_Inhibition,%
decrease from control (cat),V-C perfusion,90-180
min,Mean,74,SE,4,6,PercentChange,-74,P \< 0.01,%,Table 1 \[cite: 7750\]

\[cite_start\]Vogh_1985_CanJPhysiolPharmacol,ConditionValue,Control_Rat,NA,NA,CSF_Production,CSF_FormationRate,Rate
of formation of CSF (rat),V-C perfusion,90-180
min,Mean,9.7,SE,0.4,12,NA,NA,NR,μL/min,Table 1 \[cite: 7750\]

\[cite_start\]Vogh_1985_CanJPhysiolPharmacol,ContrastEffect,NA,Control_Rat,ACZ_Rat,CSF_Production,CSF_FormationRate_Inhibition,%
decrease from control (rat),V-C perfusion,90-180
min,Mean,55,SE,5,9,PercentChange,-55,P \< 0.01,%,Table 1 \[cite: 7750\]

\[cite_start\]Tschirgi_1954_ProcSocExpBiolMed,ConditionValue,Control,NA,NA,ICP,CSF_Pressure,Mean
control CSF pressure,Cisterna magna
needle,Baseline,Mean,104,Range,70-130,NA,13,NA,NA,NR,mm H2O,text p.374
\[cite: 4144\]

\[cite_start\]Tschirgi_1954_ProcSocExpBiolMed,ConditionValue,ACZ_50mgkg,NA,NA,ICP,CSF_Pressure_Min,Mean
minimum CSF pressure,Cisterna magna needle,30-180 min
post-drug,Mean,56,Range,40-75,NA,7,NA,NA,NR,mm H2O,text p.374 \[cite:
4144\]

\[cite_start\]Tschirgi_1954_ProcSocExpBiolMed,ConditionValue,ACZ_100mgkg,NA,NA,ICP,CSF_Pressure_Min,Mean
minimum CSF pressure,Cisterna magna needle,30-180 min
post-drug,Mean,49,Range,35-65,NA,6,NA,NA,NR,mm H2O,text p.374 \[cite:
4144\]

\[cite_start\]Tschirgi_1954_ProcSocExpBiolMed,ContrastEffect,NA,Control,ACZ_50mgkg,ICP,CSF_Pressure_Reduction,Average
% fall in pressure,Cisterna magna needle,30-180 min
post-drug,Mean,46,Range,22-62,NA,7,PercentChange,46,NR,%,text p.374
\[cite: 4144\]

\[cite_start\]Tschirgi_1954_ProcSocExpBiolMed,ContrastEffect,NA,Control,ACZ_100mgkg,ICP,CSF_Pressure_Reduction,Average
% fall in pressure,Cisterna magna needle,30-180 min
post-drug,Mean,54,Range,33-68,NA,6,PercentChange,54,NR,%,text p.374
\[cite: 4144\]
